Leqvio (Inclisiran) and Rosuvastatin Interaction: Safety, Mechanism, and Clinical Guidance

What the Leqvio label says about statins

The Leqvio label states that no formal clinical drug interaction studies were done, that inclisiran is not a substrate, inhibitor or inducer of cytochrome P450 enzymes or transporters, and that in a population pharmacokinetic analysis it did not clinically significantly change atorvastatin or rosuvastatin concentrations [1]. The label lists no specific interacting drug [1].

Why the two drugs do not use the same pathways

Inclisiran is a double-stranded small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which helps liver cells take it up. Inside hepatocytes it directs catalytic breakdown of PCSK9 messenger RNA, so less PCSK9 is made, more LDL receptors are recycled to the cell surface and more LDL-C is cleared from the blood [1]. It is not a monoclonal antibody and not a statin [1]. After a 284 mg subcutaneous dose, plasma levels peak at about 4 hours and are undetectable by 24 to 48 hours; the drug is broken down by nucleases into shorter nucleotides and is not a CYP450 or transporter substrate [1]. LDL-C lowering persists for months after each dose despite that short plasma half-life [1].

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate [2]. It is not a prodrug: more than 90% of the plasma HMG-CoA reductase inhibitory activity comes from the parent compound [2]. Only about 10% of a dose is recovered as metabolite, mainly N-desmethyl rosuvastatin formed principally by CYP2C9, and about 90% is excreted in feces [2]. Rosuvastatin is a substrate of the transporters OATP1B1 and BCRP, and its clearance does not depend on CYP3A4 to a clinically significant extent; itraconazole raised exposure only about 1.4-fold [2].

The rosuvastatin interactions that matter are transporter interactions. Cyclosporine raised rosuvastatin AUC about 7-fold and peak concentration about 11-fold, and the Crestor label says not to exceed 5 mg daily with cyclosporine [2][4]. Gemfibrozil 600 mg twice daily raised the AUC of a single 80 mg rosuvastatin dose 1.88-fold and peak concentration 2.21-fold in a crossover study of 20 healthy volunteers, and the label says to avoid that combination or, if unavoidable, to start at 5 mg and not exceed 10 mg daily [2][5]. Inclisiran is not a substrate, inhibitor or inducer of these pathways [1].

What the trials show when inclisiran is added to a statin

ORION-10 and ORION-11 enrolled 1,561 adults with atherosclerotic cardiovascular disease (ORION-10) and 1,617 adults with atherosclerotic cardiovascular disease or a risk equivalent (ORION-11), all with LDL-C still elevated on the maximum tolerated statin dose. Baseline LDL-C averaged about 105 mg/dL. Inclisiran 284 mg was given on day 1, day 90, then every 6 months; at day 510 the placebo-corrected LDL-C reduction was 52.3% in ORION-10 and 49.9% in ORION-11 [3]. Adverse events were generally similar to placebo apart from more injection-site events [3].

In ORION-9, 482 adults with heterozygous familial hypercholesterolemia and a mean baseline LDL-C of 153 mg/dL received inclisiran or placebo on days 1, 90, 270 and 450; at day 510 LDL-C fell 39.7% on inclisiran and rose 8.2% on placebo, a between-group difference of -47.9 percentage points [6].

In the pooled adult placebo-controlled trials behind the label (1,833 on Leqvio and 1,822 on placebo, median 77 weeks), injection-site reactions occurred in 8% versus 2%, arthralgia in 5% versus 4% and bronchitis in 4% versus 3%. Discontinuation for adverse reactions was 2.5% versus 1.9%, most often for injection-site reactions (0.2% versus 0%) [1].

VICTORION-Difference gives the most direct look at inclisiran alongside active rosuvastatin use. In it, 1,770 adults at high or very high cardiovascular risk were randomized to inclisiran sodium 300 mg (equivalent to 284 mg inclisiran, n=898) or to placebo (n=872), both alongside individually optimized lipid-lowering therapy that included open-label up-titration of rosuvastatin to the LDL-C goal or the maximally tolerated dose. At day 90, 84.9% of the inclisiran group reached their individual LDL-C goal versus 31.0% of the optimized-therapy group (odds ratio 12.09, P<0.001), and mean LDL-C reduction from baseline to day 360 was 59.5% versus 24.3%. Fewer inclisiran-treated participants reported a muscle-related adverse event (11.9% versus 19.2%; odds ratio 0.57, P<0.001) [7].

Is muscle risk higher with the combination?

Myopathy and rhabdomyolysis are the main muscle warnings for rosuvastatin. The Crestor label lists age 65 or older, uncontrolled hypothyroidism, renal impairment, use of certain other drugs and higher dose as risk factors, notes that Asian patients may be at higher risk, and states that myopathy risk is greater at 40 mg daily than at lower doses. Immune-mediated necrotizing myopathy is rare but has been reported [2]. The label says patients should promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever [2].

On the inclisiran side, arthralgia (joint pain) was reported by 5% of patients on Leqvio versus 4% on placebo in the pooled trials [1]. In VICTORION-Difference, muscle-related adverse events were reported by 11.9% of participants assigned to inclisiran plus optimized lipid-lowering therapy and 19.2% of those assigned optimized therapy without inclisiran; both groups could have rosuvastatin up-titrated [7]. These comparisons do not establish that adding inclisiran changes the muscle-symptom risk from rosuvastatin.

Do either drug's doses change?

Neither label asks for a dose change of one drug because of the other [1][2]. Rosuvastatin is used at 5 to 40 mg once daily depending on indication, LDL-C and cardiovascular risk, and it can be taken at any time of day with or without food [2]. The Crestor label's dose caps belong to other drugs, not to inclisiran: no more than 5 mg daily with cyclosporine, avoid gemfibrozil or start at 5 mg and cap at 10 mg daily, start at 5 mg and no more than 10 mg daily with simeprevir or several hepatitis C and HIV protease inhibitor regimens, and no more than 20 mg daily with ticagrelor, febuxostat or fostamatinib [2].

Kidney function changes rosuvastatin dosing more than inclisiran dosing. The Leqvio label calls for no dose adjustment in mild, moderate or severe renal impairment (it was not studied in end-stage renal disease) or in mild to moderate hepatic impairment (not studied in severe hepatic impairment) [1]. The Crestor label says to start at 5 mg and not exceed 10 mg daily in severe renal impairment (creatinine clearance below 30 mL/min/1.73 m2, not on hemodialysis), and lists acute liver failure or decompensated cirrhosis as contraindications [2].

Inclisiran is not self-injected: a healthcare professional gives 284 mg under the skin of the abdomen, upper arm or thigh, initially, again at 3 months, then every 6 months [1].

Monitoring and what to watch for

Inclisiran's only Warning and Precaution in the label is hypersensitivity. Anaphylaxis and angioedema have been reported after marketing, along with rash, pruritus and urticaria, and the label says patients should seek prompt medical attention for symptoms. A prior serious hypersensitivity reaction to inclisiran or an excipient is a contraindication [1]. Injection-site reactions are the most common adverse reaction in the trials (8% versus 2% on placebo) [1]. The label says LDL-C can be measured as early as 30 days after the first inclisiran dose [1].

For rosuvastatin, the Crestor label says to consider liver enzyme testing before starting and as clinically indicated; in pooled placebo-controlled trials transaminases above 3 times the upper limit of normal occurred in 1.1% on Crestor versus 0.5% on placebo [2]. The label says LDL-C can be assessed as early as 4 weeks after starting [2]. Rosuvastatin significantly increased the INR in patients taking warfarin, and the label says to check INR before starting and often enough after starting, titrating or stopping [2]. When aluminum/magnesium hydroxide antacid was taken at the same time, rosuvastatin exposure was about 50% lower; the Crestor label says to take rosuvastatin at least 2 hours before such an antacid [2]. Both labels say to discontinue when pregnancy is recognized or to consider the patient's ongoing therapeutic needs [1][2].

Does Leqvio reduce heart attacks and strokes when added to rosuvastatin?

The Leqvio label says cardiovascular outcomes trials have shown that lowering LDL-C reduces major adverse cardiovascular events in adults at increased risk treated with statins, or with PCSK9 monoclonal antibodies added to a statin. It does not report a cardiovascular outcomes result for inclisiran itself [1]. The inclisiran trials described here measured LDL-C rather than cardiovascular events [3][6].